Judge, Daniel P.
Kristen, Arnt V.
Grogan, Martha
Maurer, Mathew S.
Falk, Rodney H.
Hanna, Mazen
Gillmore, Julian
Garg, Pushkal
Vaishnaw, Akshay K.
Harrop, Jamie
Powell, Christine
Karsten, Verena
Zhang, Xiaoping
Sweetser, Marianne T.
Vest, John
Hawkins, Philip N.
Funding for this research was provided by:
Alnylam Pharmaceuticals (n/a)
Article History
First Online: 15 February 2020
Change Date: 16 June 2020
Change Type: Correction
Change Details: The original article contained incorrect terminology for one of the cardiac measures; throughout the manuscript and supplementary information ���<i>intraventricular septum wall thickness</i>��� should have been given as ���<i>interventricular septum wall thickness</i>���. Corrections should also be noted for Tables 1 and 4: in the Table 1 legend <i>���Low risk ��� Neither above at baseline���</i> should read <i>���Low risk ��� Neither above threshold at baseline���</i>; in Table 4, the rows <i>���Mild: eGFR > 60 to < 90 ml/min/1.73 m</i><sup><i>2</i></sup>��� and <i>���Moderate: eGFR > 30 to < 60 ml/min/1.73 m</i><sup><i>2</i></sup>��� should read <i>���Mild: eGFR ��� 60 to < 90 ml/min/1.73 m</i><sup><i>2</i></sup>��� and <i>���Moderate: eGFR ��� 30 to < 60 ml/min/1.73 m</i><sup><i>2</i></sup>���, respectively. The original article also contained a mistake in the text of the Pharmacokinetics sub-section of Results; <i>���There were no apparent differences in revusiran C</i><sub><i>max</i></sub><i>between patients with mild (eGFR: 30 and < 60 ml/min/1.73 m</i><sup><i>2</i></sup>) <i>or moderate (eGFR: 60 to < 90 ml/min/1.73 m</i><sup><i>2</i></sup>) <i>renal impairment when compared with patients with normal (eGFR: ��� 90 ml/min/1.73 m</i><sup><i>2</i></sup>) <i>renal function at Weeks 0, 26, and 52 (p > 0.20) (Supplementary Fig. 6)���</i> should read <i>���There were no apparent differences in revusiran C</i><sub><i>max</i></sub><i>between patients with mild (eGFR: ��� 60 to < 90 ml/min/1.73 m</i><sup><i>2</i></sup>) <i>or moderate (eGFR: ��� 30 and < 60 ml/min/1.73 m</i><sup><i>2</i></sup>) <i>renal impairment when compared with patients with normal (eGFR: ��� 90 ml/min/1.73 m</i><sup><i>2</i></sup>) <i>renal function at Weeks 0, 26, and 52 (p > 0.20) (Supplementary Fig. 6)���</i>.
Compliance with Ethical Standards
:
: Daniel P. Judge received support for clinical trial participation, scientific consultation, and writing from Alnylam Pharmaceuticals, Inc. and support for scientific consultation from GlaxoSmithKline plc and Pfizer. Arnt V. Kristen received a research grant, support for scientific consultation, and symposia honoraria from Alnylam Pharmaceuticals, Inc. Martha Grogan received support for clinical trial participation from Alnylam Pharmaceuticals, Inc., Eidos Therapeutics, Inc., Pfizer, and Prothena Corporation plc. Matthew S. Maurer received support for clinical research from Alnylam Pharmaceuticals, Inc., Eidos Therapeutics, Inc., Pfizer, and Prothena Corporation plc; support for Data and Safety Monitoring Board participation from Prothena Corporation plc; and support for steering committee participation from Pfizer. Rodney H. Falk received support for consultancy and research from Akcea Therapeutics, Inc. Eidos Therapeutics, Inc., and Alnylam Pharmaceuticals, Inc. Mazen Hanna received support for advisory board participation from Alnylam Pharmaceuticals, Inc., Akcea Therapeutics, Inc, Eidos Therapeutics, Inc., and Pfizer. Julian Gillmore received support for clinical trial and advisory board participation from Alnylam Pharmaceuticals, Inc. Pushkal Garg, Akshay K. Vaishnaw, Jamie Harrop, Christine Powell, Verena Karsten, Marianne Sweetser, John Vest, and Xiaoping Zhang are employees of, and own stock in, Alnylam Pharmaceuticals, Inc.
: This study was approved by central and local institutional review boards or ethics committees and performed in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. A DMC, comprising a cardiologist, hepatologist, and statistician, reviewed all pertinent benefit–risk data and an independent clinical adjudication committee performed blinded adjudication of the causes of hospitalization and death.
: All patients in this study gave their informed consent.